BR112019000215A2 - depleção de cistina mediada por enzima humana - Google Patents
depleção de cistina mediada por enzima humanaInfo
- Publication number
- BR112019000215A2 BR112019000215A2 BR112019000215-4A BR112019000215A BR112019000215A2 BR 112019000215 A2 BR112019000215 A2 BR 112019000215A2 BR 112019000215 A BR112019000215 A BR 112019000215A BR 112019000215 A2 BR112019000215 A2 BR 112019000215A2
- Authority
- BR
- Brazil
- Prior art keywords
- cyst
- human enzyme
- amino
- methods
- mediated
- Prior art date
Links
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 229960003067 cystine Drugs 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 206010011732 Cyst Diseases 0.000 abstract 3
- 208000031513 cyst Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical class [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359018P | 2016-07-06 | 2016-07-06 | |
| US62/359,018 | 2016-07-06 | ||
| PCT/US2017/040897 WO2018009663A1 (en) | 2016-07-06 | 2017-07-06 | Human-enzyme mediated depletion of cystine for treating patients with cystinuria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019000215A2 true BR112019000215A2 (pt) | 2019-04-24 |
Family
ID=60892921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019000215-4A BR112019000215A2 (pt) | 2016-07-06 | 2017-07-06 | depleção de cistina mediada por enzima humana |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180008681A1 (https=) |
| EP (1) | EP3481425A4 (https=) |
| JP (1) | JP2019520392A (https=) |
| KR (1) | KR20190026813A (https=) |
| CN (1) | CN109562178A (https=) |
| AU (1) | AU2017291842A1 (https=) |
| BR (1) | BR112019000215A2 (https=) |
| CA (1) | CA3028771A1 (https=) |
| IL (1) | IL263997A (https=) |
| MX (1) | MX383505B (https=) |
| WO (1) | WO2018009663A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2531597B1 (en) | 2010-02-04 | 2021-01-06 | AEMase, Inc. | Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof |
| KR102244750B1 (ko) | 2013-08-29 | 2021-04-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 치료적 목적을 위한 조작된 영장류 ｌ-메티오니나제 |
| KR102269209B1 (ko) | 2013-08-29 | 2021-06-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항신생물제로서 조작된 영장류 시스틴/시스테인 분해 효소 |
| US10865403B2 (en) | 2017-05-12 | 2020-12-15 | Board Of Regents, The University Of Texas System | Engineered primate cystine/cysteine degrading enzymes for therapeutic uses |
| KR102680776B1 (ko) | 2017-05-12 | 2024-07-04 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 고호모시스테인혈증 및 호모시스틴뇨증 환자를 치료하기 위한 인간-효소 매개된 호모시스테인의 고갈 |
| SG11202104205XA (en) | 2018-10-26 | 2021-05-28 | Univ Texas | Engineered primate cystine/cysteine degrading enzymes for therapeutic uses |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| US20060275279A1 (en) * | 2005-06-06 | 2006-12-07 | Rozzell J D | Methods for dissolving cystine stones and reducing cystine in urine |
| EP1749822B1 (en) * | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
| HUE042177T2 (hu) * | 2009-12-01 | 2019-06-28 | Translate Bio Inc | Szteroidszármazék mRNS szállítására humán genetikai betegségekben |
| KR102244750B1 (ko) | 2013-08-29 | 2021-04-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 치료적 목적을 위한 조작된 영장류 ｌ-메티오니나제 |
| KR102269209B1 (ko) * | 2013-08-29 | 2021-06-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항신생물제로서 조작된 영장류 시스틴/시스테인 분해 효소 |
-
2017
- 2017-07-06 CA CA3028771A patent/CA3028771A1/en not_active Abandoned
- 2017-07-06 AU AU2017291842A patent/AU2017291842A1/en not_active Abandoned
- 2017-07-06 BR BR112019000215-4A patent/BR112019000215A2/pt not_active Application Discontinuation
- 2017-07-06 WO PCT/US2017/040897 patent/WO2018009663A1/en not_active Ceased
- 2017-07-06 US US15/643,436 patent/US20180008681A1/en not_active Abandoned
- 2017-07-06 JP JP2019500316A patent/JP2019520392A/ja not_active Ceased
- 2017-07-06 CN CN201780041950.0A patent/CN109562178A/zh active Pending
- 2017-07-06 KR KR1020197003180A patent/KR20190026813A/ko not_active Withdrawn
- 2017-07-06 EP EP17824888.6A patent/EP3481425A4/en not_active Withdrawn
- 2017-07-06 MX MX2019000235A patent/MX383505B/es unknown
-
2018
- 2018-12-27 IL IL263997A patent/IL263997A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109562178A (zh) | 2019-04-02 |
| KR20190026813A (ko) | 2019-03-13 |
| JP2019520392A (ja) | 2019-07-18 |
| WO2018009663A1 (en) | 2018-01-11 |
| MX383505B (es) | 2025-03-14 |
| EP3481425A1 (en) | 2019-05-15 |
| AU2017291842A1 (en) | 2019-01-17 |
| EP3481425A4 (en) | 2020-02-26 |
| IL263997A (en) | 2019-02-03 |
| MX2019000235A (es) | 2019-05-30 |
| CA3028771A1 (en) | 2018-01-11 |
| US20180008681A1 (en) | 2018-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019000215A2 (pt) | depleção de cistina mediada por enzima humana | |
| BR112016004095A2 (pt) | administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores | |
| BR112018014288A2 (pt) | métodos e composições para o tratamento de doença neurológica | |
| WO2015031726A3 (en) | Engineered primate l-methioninase for therapeutic purposes | |
| MX2024012897A (es) | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer | |
| BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
| MX2019010040A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| BR112018008326A2 (pt) | composições e métodos para o tratamento de câncer | |
| PH12019501414A1 (en) | Amino acid compositions and methods for the treatment of liver diseases | |
| BR112015020235A2 (pt) | fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| EP4477662A3 (en) | Nucleic acid molecules and uses thereof | |
| BR112017007765A2 (pt) | composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo | |
| BR112016027773A2 (pt) | peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica | |
| BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
| BR112022007677A2 (pt) | L-asparaginase recombinante | |
| UA108193C2 (uk) | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| ZA202006077B (en) | Human kynureninase enzymes and uses thereof | |
| DOP2012000265A (es) | Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores. | |
| CL2019003248A1 (es) | Disminución de homocisteína mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria. | |
| WO2017151860A8 (en) | Human kynureninase enzyme variants having improved pharmacological properties | |
| BR112015021483A2 (pt) | arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer | |
| BR112019009581A2 (pt) | composição farmacêutica para evitar ou tratar hepatite, fibrose hepática, e cirrose hepática que compreende proteínas de fusão | |
| BR112018010160A2 (pt) | inibidor da c1 esterase humana recombinante e usos do mesmo | |
| BR112019003816A2 (pt) | composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |